Voyager Therapeutics, Inc. (VYGR)Healthcare | Biotechnology | Lexington, United States | NasdaqGS
3.54 USD
+0.08
(2.312%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.53 -0.01 (-0.010%) ⇩ (Aug. 28, 2026, 7:39 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:50 a.m. EDT
The investment case for Voyager Therapeutics is currently broken by a severe deterioration in both business fundamentals and market sentiment. The company is hemorrhaging cash, with operating cash flow running at -$120 million annually against a tiny revenue base of roughly $34 million. This financial distress is compounded by a crushing multi-year price trajectory; the stock has lost nearly 76% of its value over the last nine years, with the trailing twelve months seeing a brutal 48.5% decline. While analysts maintain a 'strong buy' rating based on potential future inflection points for their tau therapies, the current reality is a deep value trap where the balance sheet is eroding and the stock price has already priced in almost all optimism. The options market confirms this pessimism, with traders aggressively buying protection at lower strikes rather than betting on a bounce. Until there is concrete evidence of a revenue turnaround or a successful clinical milestone that can reverse the bleeding, the risk-reward profile remains heavily skewed toward further decline. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.124082 |
| AutoETS | 0.131343 |
| AutoTheta | 0.131420 |
| AutoARIMA | 0.145771 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 6.00 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.108 |
| Excess Kurtosis | -1.48 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 21.096 |
| Revenue per Share | 0.58 |
| Market Cap | 218,127,536 |
| Forward P/E | -2.77 |
| Beta | 1.31 |
| Website | https://www.voyagertherapeutics.com |
As of Aug. 22, 2026, 4:50 a.m. EDT: Speculators are positioning defensively with heavy put volume at strikes significantly below the current price ($2.00 and $3.00), while call interest remains concentrated near the money or slightly out-of-the-money. This imbalance suggests a market expectation of further downside or a lack of conviction in a near-term recovery, despite the presence of some long-dated call activity.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.033519566 |
| Address1 | 75 Hayden Avenue |
| All Time High | 31.91 |
| All Time Low | 2.46 |
| Ask | 4.39 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 423,720 |
| Average Daily Volume3 Month | 599,850 |
| Average Volume | 599,850 |
| Average Volume10Days | 423,720 |
| Beta | 1.308 |
| Bid | 3.52 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 2.88 |
| City | Lexington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.54 |
| Current Ratio | 7.505 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.555 |
| Day Low | 3.36 |
| Debt To Equity | 21.096 |
| Display Name | Voyager Therapeutics |
| Earnings Call Timestamp End | 1,741,725,000 |
| Earnings Call Timestamp Start | 1,741,725,000 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,794,254,400 |
| Earnings Timestamp Start | 1,794,254,400 |
| Ebitda | -109,867,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.223 |
| Enterprise To Revenue | 3.899 |
| Enterprise Value | 134,356,528 |
| Eps Current Year | -1.70466 |
| Eps Forward | -1.27902 |
| Eps Trailing Twelve Months | -1.81 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.341 |
| Fifty Day Average Change | 0.19899988 |
| Fifty Day Average Change Percent | 0.05956297 |
| Fifty Two Week Change Percent | -3.3519566 |
| Fifty Two Week High | 5.55 |
| Fifty Two Week High Change | -2.0100002 |
| Fifty Two Week High Change Percent | -0.3621622 |
| Fifty Two Week Low | 2.94 |
| Fifty Two Week Low Change | 0.5999999 |
| Fifty Two Week Low Change Percent | 0.2040816 |
| Fifty Two Week Range | 2.94 - 5.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,447,252,200,000 |
| Float Shares | 44,467,208 |
| Forward Eps | -1.27902 |
| Forward P E | -2.767744 |
| Free Cashflow | -77,310,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 141 |
| Fullday Change | 0.0799999 |
| Fullday Change Percent | 2.31214 |
| Fullday Price | 3.5301 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | -2.3680902 |
| Gross Profits | -81,602,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.14840999 |
| Held Percent Institutions | 0.57868 |
| Implied Shares Outstanding | 61,617,948 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. |
| Long Name | Voyager Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 218,127,536 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_256887902 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -107,728,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 213,198,100 |
| Number Of Analyst Opinions | 9 |
| Open | 3.46 |
| Operating Cashflow | -120,572,000 |
| Operating Margins | -8.3387 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 857 259 5340 |
| Post Market Change | -0.009899855 |
| Post Market Change Percent | -0.27965692 |
| Post Market Price | 3.5301 |
| Post Market Time | 1,787,960,350 |
| Previous Close | 3.46 |
| Price Eps Current Year | -2.0766604 |
| Price Hint | 4 |
| Price To Book | 1.2291666 |
| Price To Sales Trailing12 Months | 6.33006 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.162 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.0799999 |
| Regular Market Change Percent | 2.31214 |
| Regular Market Day High | 3.555 |
| Regular Market Day Low | 3.36 |
| Regular Market Day Range | 3.36 - 3.555 |
| Regular Market Open | 3.46 |
| Regular Market Previous Close | 3.46 |
| Regular Market Price | 3.54 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 406,051 |
| Return On Assets | -0.27337 |
| Return On Equity | -0.54091 |
| Revenue Growth | -0.391 |
| Revenue Per Share | 0.58 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 61,617,948 |
| Shares Percent Shares Out | 0.064 |
| Shares Short | 3,945,546 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 3,837,218 |
| Short Name | Voyager Therapeutics, Inc. |
| Short Percent Of Float | 0.0749 |
| Short Ratio | 6.95 |
| Source Interval | 15 |
| State | MA |
| Symbol | VYGR |
| Target High Price | 25.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 14.88889 |
| Target Median Price | 12.0 |
| Total Cash | 116,338,000 |
| Total Cash Per Share | 1.888 |
| Total Debt | 32,567,000 |
| Total Revenue | 34,459,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.81 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.7959 |
| Two Hundred Day Average Change | -0.25590014 |
| Two Hundred Day Average Change Percent | -0.06741488 |
| Type Disp | Equity |
| Volume | 406,051 |
| Website | https://www.voyagertherapeutics.com |
| Zip | 2,421 |